肝硬化腹水患者预后细化:急性与非急性失代偿的影响
这项单中心纵向队列研究纳入505例以腹水为首发失代偿事件的肝硬化患者,比较急性失代偿(AD,296例)与非急性失代偿(NAD,209例)的临床病程差异。中位随访4.4年期间,AD患者进一步失代偿发生率和无移植死亡率均高于NAD,且住院AD患者死亡风险最高;C反应蛋白可预测AD患者的无移植死亡。
要点
- 以腹水为首发失代偿的肝硬化患者中,58.6%符合AD标准,41.4%符合NAD标准。
- AD较NAD的进一步失代偿12个月累积发生率更高(19%对33%),无移植死亡风险更高(SHR 1.43)。
- 住院AD较非住院NAD的无移植死亡风险升高(SHR 1.89),C反应蛋白可预测AD的无移植死亡。
核心结论
- 将患者分类为AD与NAD可识别出进一步失代偿和无移植死亡风险不同的亚组。
研究设计与样本
- 单中心纵向队列研究纳入505例以腹水为首发失代偿事件的肝硬化患者,随访至进一步失代偿、原位肝移植或死亡。
- AD定义为3级腹水或腹水伴自发性细菌性腹膜炎或急性肾损伤,NAD定义为2级腹水。
主要发现
- 505例患者中296例(58.6%)符合AD标准,其中216例(73.0%)需住院;209例(41.4%)为NAD,其中107例(51.2%)需住院。
- 中位4.4年随访期间,65.1%发生进一步失代偿,27.7%发生慢加急性肝衰竭,10.9%接受原位肝移植,51.1%死亡。
- AD较NAD的进一步失代偿发生率更高(12个月时分别为19%和33%),无移植死亡风险更高(SHR 1.43,95%CI 1.12-1.82,p=0.004)。
- 按住院分层后,AD仅在需住院的病例中与死亡风险增加相关(住院AD vs 非住院NAD的SHR 1.89,95%CI 1.35-2.65,p<0.001)。
- C反应蛋白可预测AD的无移植死亡(每对数变化SHR 1.20,95%CI 1.02-1.41,p=0.032),但不能预测NAD的无移植死亡。
关键数值与推荐
- AD定义为3级腹水或腹水伴自发性细菌性腹膜炎或急性肾损伤,NAD定义为2级腹水。
- 住院AD vs 非住院NAD的无移植死亡SHR为1.89(95%CI 1.35-2.65,p<0.001)。
- AD vs NAD的无移植死亡SHR为1.43(95%CI 1.12-1.82,p=0.004)。
- AD中C反应蛋白每对数变化预测无移植死亡的SHR为1.20(95%CI 1.02-1.41,p=0.032)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A more granular understanding of hepatic decompensation in cirrhosis has led to the classification of acute decompensation (AD) and non-acute decompensation (NAD). In this study, we assessed differences in the clinical course of AD versus NAD in patients with ascites as the first decompensation event. METHODS: 505 cirrhosis patients with ascites as first decompensation were included in this single-center longitudinal cohort study and followed until further decompensation, orthotopic liver transplantation (OLT), or death. AD was defined as grade 3 ascites or ascites with spontaneous bacterial peritonitis (SBP) or acute-kidney injury (AKI), while NAD was defined as grade 2 ascites. Hospitalisation was recorded. RESULTS: Among 505 patients, 296 (58.6%) met the criteria for AD, with 216 (73.0%) requiring hospitalisation. NAD occurred in 209 (41.4%), with 107 (51.2%) requiring hospitalisation. During a median 4.4-year follow-up, further decompensation occurred in 65.1%, acute-on-chronic liver failure (ACLF) in 27.7%, 10.9% underwent OLT, and 51.1% died. Patients with AD had a higher incidence of further decompensation (at 12 months: 19% and 33%) and a higher risk of transplant-free mortality (subdistribution hazard ratio [SHR]: 1.43 [95% CI: 1.12-1.82], p = 0.004) versus NAD. When stratified by hospitalisation, AD was associated with an increased risk of mortality only in cases requiring hospitalisation (SHR for hospitalised AD vs. non-hospitalised NAD: 1.89, 95% CI: 1.35-2.65, p < 0.001). Inflammation (C-reactive protein) predicted transplant-free mortality in AD (SHR per log-change: 1.20 [95% CI: 1.02-1.41], p = 0.032) but not NAD. CONCLUSIONS: Classifying patients as AD versus NAD identified subgroups with different risks for further decompensation and transplant-free mortality.
引用
- Simonis L, Balcar L, Schedlbauer A, et al. Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non-Acute Decompensation. Aliment Pharmacol Ther. 2025. PMID: 40719565. doi:10.1111/apt.70302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。